CIA
SLS icon

Concurrent Investment Advisors’s SELLAS Life Sciences SLS Stock Holding History

Concurrent Investment Advisors’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,085
Closed -$42.7K – 2198
2026
Q1 		$42.7K Hold
10,085
– – ﹤0.01% 1878
2025
Q4 		$38K Buy
+10,085
New +$19.6K ﹤0.01% 1748

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Concurrent Investment Advisors's SLS Position: Q2 2026 in Review

Concurrent Investment Advisors sold out of SELLAS Life Sciences (SLS) in Q2 2026, closing a stake of 10,085 shares — an estimated $42.7K sold.

Concurrent Investment Advisors first reported a position in SLS in Q4 2025 and held it in 2 quarters. The position peaked at $42.7K in Q1 2026. 193 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Concurrent Investment Advisors reported no remaining SELLAS Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Concurrent Investment Advisors sold 10,085 SELLAS Life Sciences shares in Q2 2026, an estimated $42.7K.
  • Concurrent Investment Advisors first reported a position in SELLAS Life Sciences in Q4 2025 and held it in 2 quarters.
  • Concurrent Investment Advisors's SELLAS Life Sciences position peaked at $42.7K in Q1 2026.
  • 193 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.